Impact of the bowel-screening programme on the diagnosis of colorectal cancer in Ayrshire and Arran

Colorectal Disease

Volumn 15, Issue 1, 2013, Pages 34-41

  Roxburgh, C S D ^a   Mctaggart, F ^a   Balsitis, M ^a   Diament, R H ^a  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; Pathology; Referral category; Screening; TNM stage

Indexed keywords

ADULT; AGED; ARTICLE; BOWEL SCREENING; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; COLON TUMOR; COLORECTAL CANCER; ENDOSCOPIC SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; SCREENING;

AGED; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EMERGENCIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OCCULT BLOOD; REFERRAL AND CONSULTATION; SCOTLAND;

EID: 84871646319     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2012.03100.x     Document Type: Article

References (24)

1. Cruk CR. (2008) Bowel Cancer - UK incidence statistics. http://info.cancerresearch.org/cancerstats/types/bowel/incidence (accessed August 2011).
2. Scottish Bowel Screening Programme. http://www.bowelscreening.scot.nhs.uk (accessed August 2011).
3. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal occult blood test. Lancet 1996; 348: 1467-71.
5. Mandel JS, Bond JH, Church JR et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med 1993; 328: 1365-71.
6. UK Colorectal screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. Br Med J 2004; 329: 133-5
7. Ellul P, Fogden E, Simpson CL et al. Downstaging of colorectal cancer by the National Bowel Cancer Screening programme in England: first round data from the first centre. Colorectal Dis 2010; 12: 420-2.
8. NHS Ayrshire and Arran. http://www.nhsayrshireandarran.com (accessed August 2011).
9. Williams GT, Quirke P, Shepherd NA. Dataset for Colorectal Cancer (2007 2nd edition). Royal College of Pathologists, http://www.rcpath.org/resources/pdf/G049-ColorectalDataset-Sep07.pdf (accessed August 2011).
10. Carstairs V, Morris R. (1991) Deprivation and Health in Scotland. University Press, Aberdeen.
11. Information Services Division Scotland. http://www.isdscotland.org (accessed August 2011).
12. Hole DJ, McArdle CS. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer. Br J Surg 2002; 89: 586-90.
13. Crozier JE, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg 2009; 197: 544-9.
14. Steele RJ, McClements P, Watling C et al. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site. Gut 2012; 61: 576-81.
15. Harmston C, Hunter J, Wong L. Does the location of screen-detected cancers differ from that seen in the unscreened population?Colorectal Dis 2010; 12: 324-6.
16. Ahmed S, Leslie A, Thaha MA, Carey FA, Steele RJ. Lower gastrointestinal symptoms are not predictive of colorectal neoplasia in a faecal occult blood screen positive population. Br J Surg 2005; 92: 478-81.
17. Atkin WS, Edwards R, Kralj-Hans I et al. UK Flexible Sigmoidoscopy Trial Investigators Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre controlled trial. Lancet 2010; 375: 1624-33.
18. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51: 65-9.
19. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?Ann Oncol 2003; 14: 1026-38.
20. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-63.
21. Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG, McMillan DC. Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol 2011; 18: 997-1005.
22. Atkin WS. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-300.
23. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007; 56: 677-84.
24. Macafee DA, West J, Scholefield JH, Whynes DK. Hospital costs of colorectal cancer care. Clin Med Oncol 2009; 3: 27-37.